LawPlayer
My bookmarksSign up freeSign up free
Source

2014/176/EU: Commission Implementing Decision of 27 March 2014 as regards a Union financial contribution towards a coordinated control plan with a view to establishing the prevalence of fraudulent practices in the marketing of certain foods (notified under document C(2014) 1912)

2014/176/EU: Commission Implementing Decision of 27 March 2014 as regards a Union financial contribution towards a coordinated control plan with a view to establishing the prevalence of fraudulent practices in the marketing of certain foods (notified under document C(2014) 1912)

Decision · 12 articles

Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Subject matter

Article 1

Open ↗

1.   The Union shall contribute to the costs incurred by the Member States for the application of the coordinated control plan referred to in Recommendation 2014/180/EU (hereinafter ‘Commission Recommendation’), with a total maximum amount of EUR 145 440. 2.   The Union shall contribute to the costs incurred by the Centre Wallon de Recherches agronomiques (CRA-W), Gembloux, Belgium, for the calibration and coordination of the testing method for undeclared animal species in meat and meat products, with a total maximum amount of EUR 20 000. 3.   The costs referred to in paragraphs 1 and 2 shall be financed from budgetary line 17.0403.

Eligible costs to Member States

Article 2

Open ↗

1.   The Union contribution referred to in Article 1 paragraph 1 shall take the form of a reimbursement of 50 % of the costs of the tests performed by the competent authorities to implement the control plan referred to in point 1 of the Commission Recommendation. 2.   The Union contribution shall not exceed: (a) on average EUR 60 per test; (b) the amounts indicated in Annex I. 3.   Only the costs indicated in Annex II shall be eligible for contribution.

Eligible costs to Centre Wallon de Recherches agronomiques (CRA-W), Gembloux, Belgium

Article 3

Open ↗

1.   The Union contribution referred to in Article 1 paragraph 2 shall take the form of a reimbursement of 100 % of the costs of the tasks related to calibration and coordination of the testing method used in the coordinated control plan referred to in the Commission Recommendation. 2.   The following costs are eligible: (a) personnel specifically allocated entirely or in part for carrying out the tasks in the premises of the laboratory; the costs are limited to actual salaries plus social security charges and other statutory costs included in the remuneration; (b) consumables related to preparation of the standard samples; (c) shipment costs; (d) overheads equal to 7 % of the sum of the costs in (a), (b), and (c). 3.   The costs shall be reported by 31 August 2014 in accordance with the format in Annex IV of this Decision.

Eligibility rules

Article 4

Open ↗

1.   The Union contribution referred to in Article 1 paragraph 1 is subject to the following conditions: (a) the tests have been performed in accordance with the terms of the Commission Recommendation; (b) the Member States have provided the Commission with the report referred to in the Commission Recommendation within the deadline provided for therein; (c) by 31 August 2014, the Member States have provided the Commission, in electronic form, with a financial report according to the format laid out in Annex III of this Decision. 2.   The Commission may reduce the amount of the contribution referred to in Article 1 in cases where the conditions referred to in para 1 are not met, having regard to the nature and gravity of the non-compliance and to the potential financial loss for the Union. 3.   At the request of the Commission, the Member States shall provide the documents providing evidence of the costs incurred for which a reimbursement is claimed in accordance with Article 2.

Currency and conversion rate

Article 5

Open ↗

1.   The expenditure submitted by the Member States for a financial contribution by the Union shall be expressed in euro and shall exclude value added tax and all other taxes. 2.   Where the expenditure of a Member State is in a currency other than the euro, the Member State concerned shall convert it into euro by applying the most recent exchange rate set by the European Central Bank, prior to the first day of the month in which the application is submitted by the Member State.

Article 6

Open ↗

This Decision constitutes a financing decision in the meaning of Article 84 of the Financial Regulation.

Article 7

Open ↗

This Decision shall be applicable from the date of publication of the Commission Recommendation.

Supplementary provisions

ANNEX ISupplementary provisions

Open ↗

ANNEX I MAXIMUM AMOUNT OF THE EU CONTRIBUTION REFERRED TO IN ARTICLE 2(2)(B) Member State Recommended sample numbers Extrapolated number of samples in 2 nd round (5 %) Maximum EU contribution per test Maximum EU contribution per MS TOTAL EU contribution France, Germany, Italy, United Kingdom, Spain, Poland 150 8 60 9 480 56 880 Romania, Netherlands, Belgium, Greece, Portugal, Czech Republic, Hungary, Sweden, Austria, Bulgaria 100 5 60 6 300 63 000 Lithuania, Slovakia, Denmark, Ireland, Finland, Latvia, Croatia 50 3 60 3 180 22 260 Slovenia, Estonia, Cyprus, Luxembourg, Malta 10 1 60 660 3 300 TOTAL         145 440

ANNEX IISupplementary provisions

Open ↗

ANNEX II ELIGIBLE EXPENDITURE AS REFERRED TO IN ARTICLE 2(3) The expenditure eligible for a financial contribution by the Union for carrying out the tests mentioned in this Implementing Decision, shall be limited to the costs incurred by the Member States for: (a) the purchase of test kits, reagents and all consumables identifiable and especially used for carrying out the tests; (b) personnel, whatever the status, specifically allocated entirely or in part for carrying out the tests in the premises of the laboratory; the costs are limited to actual salaries plus social security charges and other statutory costs included in the remuneration; and; (c) overheads equal to 7 % of the sum of the costs referred to in (a) and (b), unless the Member State is using a commercial laboratory.

ANNEX IIISupplementary provisions

Open ↗

ANNEX III Financial report as referred to in Article 4(1)(c) DNA Staff Hours Cost/hour Staff cost (1) (2) (3)                     Subtotal staff (5) Test kits, reagents, consumables Quantity Unit cost Total cost (6) (7) (8)                 Subtotal consumables (10) TOTAL Total including overheads (11) × (1,07) Alternative financial report as referred to in Article 4(1)(c), when using a commercial laboratory Name of commercial laboratory   Number of samples sent to the laboratory   Total sum of invoice from commercial laboratory

ANNEX IVSupplementary provisions

Open ↗

ANNEX IV FINANCIAL REPORT AS REFERRED TO IN ARTICLE 3(3) STAFF Category hours Cost/hour Staff cost (1) (2) (3)                 Consumables Category Quantity Cost/unit Cost consumables (5) (6) (7)                 Shipment costs Specify Quantity Cost/unit Cost shipment (9) (10) (11)             TOTAL     TOTAL + overhead

Other acts of the same type
Council Decision (EU) 2025/426 of 24 February 2025 on the signing, on behalf of the European Union, of the Agreement between the European Union and the Federative Republic of Brazil on cooperation with and through the European Union Agency for Law Enforcement Cooperation (Europol) and the Federal Police of BrazilCommission Implementing Decision (EU) 2025/349 of 21 February 2025 postponing the expiry date of the approval of spinosad for use in biocidal products of product-type 18 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the CouncilCommission Implementing Decision (EU) 2025/357 of 21 February 2025 not approving 5-chloro-2-methyl-2H-isothiazol-3-one (CIT) as an active substance for use in biocidal products of product-type 6 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the CouncilCommission Implementing Decision (EU) 2025/360 of 21 February 2025 postponing the expiry date of the approval of bromoacetic acid for use in biocidal products of product-type 4 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the CouncilCommission Implementing Decision (EU) 2025/362 of 21 February 2025 postponing the expiry date of the approval of cypermethrin for use in biocidal products of product-type 8 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the CouncilCommission Implementing Decision (EU, Euratom) 2025/363 of 21 February 2025 amending Implementing Decision (EU, Euratom) 2023/2825 as regards the rules on risk management and compliance framework for borrowing, debt management, liquidity management and lending operations and non-competitive auction allocationCommission Decision (EU, Euratom) 2025/369 of 21 February 2025 establishing the role of the Chief Risk Officer overseeing the financial risks arising from the Union’s financial operationsDecision (EU) 2025/451 of the European Central Bank of 21 February 2025 amending Decision (EU) 2024/461 on the reporting by national competent authorities to the European Central Bank of information on remuneration, gender pay gap, approved higher ratios and high earners for the purposes of benchmarking (ECB/2024/2) (ECB/2025/7)Commission Decision (EU) 2025/1191 of 21 February 2025 on State aid SA. 33769 – C/2015 (ex NN/2015) (ex CP/2011) implemented by Romania for Târgu Mureş Transylvania Airport (notified under document C(2025) 1127)Commission Decision (EU) 2025/2370 of 21 February 2025 on the State aid measure SA.106107 (2024/N) which Belgium is planning to implement for the lifetime extension of two nuclear reactors (Doel 4 and Tihange 3) (notified under document C(2025) 1070)Commission Implementing Decision (EU) 2025/337 of 20 February 2025 on the harmonised standards for pyrotechnic articles drafted in support of Directive 2013/29/EU of the European Parliament and of the CouncilCommission Implementing Decision (EU) 2025/383 of 20 February 2025 amending Implementing Decision (EU) 2024/2207 concerning certain emergency measures relating to sheep pox and goat pox in Greece (notified under document C(2025) 1248)

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

Contents

What to look at next